Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open‐label clinical trial

M. Friedman, Deborah; Llanos, Carolina; M. Izmirly, Peter; Brock, Brigit; Byron, John; Copel, Joshua; Cummiskey, Karen; Anne Dooley, Mary; Foley, Jill; Graves, Cornelia; Hendershott, Colleen; Kates, Richard; V. Komissarova, Elena; Miller, Michelle; Paré, Emmanuelle; K. L. Phoon, Colin; Prosen, Tracy; Reisner, Dale; Ruderman, Eric; Samuels, Philip; K. Yu, Jerry; Y. Kim, Mimi; P. Buyon, Jill

doi:10.1002/art.27308

Public

Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open‐label clinical trial

Shared by NobleBlocks on Mar 28, 2010 • 12:00 AM UTC

Authors:

Deborah M. Friedman

Carolina Llanos

Peter M. Izmirly

Abstract

Abstract Objective The recurrence rate of anti‐SSA/Ro–associated congenital heart block (CHB) is 17%. Sustained reversal of third‐degree block has never been achieved. Based on potential reduction of maternal autoantibody titers as well as fetal inflammatory responses, intravenous immunoglobulin (IV...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!